Results from the first large-scale, independent, comparative study of automated diabetic retinopathy (DR) screening technologies, show that EyeArt™ software device rates highest among those tested in sensitivity.
Eyenuk, Inc., is a developer of advanced retinal image analysis solutions to identify eye disease with the goal of quickly and accurately identifying patients suffering from potentially blinding eye diseases and preserving their vision. The company is developing a portfolio of products based on its proprietary retinal image analysis technology to identify and track the progression of eye diseases, including diabetic retinopathy(DR) and age-related macular degeneration (AMD).
Evenuk’s EyeArt™ has received CE Marking and is commercially available in the European Union, yet remains investigational in the U.S.
Study results were presented by Catherine Egan, MD, Consultant Ophthalmologist, Moorfields Eye Hospital, London in an oral presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).
The study of 142,018 images from 20,258 consecutive patients reviewed three CE marked automated retinal image analysis software solutions for effectiveness and cost-effectiveness. The study was funded by the National Institute for Health Research HTA program, a Fight for Sight grant, and the Department of Health’s NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital.
The study investigators concluded that EyeArt achieved acceptable sensitivity for referable retinopathy when compared with a quality-assured, real world human grader working in a high volume clinical setting as a reference standard, and had specificity sufficient to make it a cost effective alternative to a purely manual grading approach.
“The first large-scale, independent study of automated DR screening technologies showed that automation, such as that provided by EyeArt, can not only increase our screening capability, but do it with very high levels of sensitivity,” said Adnan Tufail, MD, FRCOphth, principal investigator of the study and Consultant Ophthalmologist with Moorfields Eye Hospital, London. “Our comprehensive health economic analysis further showed that this type of novel technology can be a cost effective alternative to purely manual grading.”
“By fully automating the entire screening process, including imaging, grading, and reporting in a single office visit, we have combined speed and accuracy into what we believe is the most advanced DR screening technology available,” said Eyenuk Chief Executive Officer, Kaushal Solanki, PhD. “The technology is also designed to work effectively with image quality commonly found in diabetes patients and with imaging protocols and cameras typically used in screening setups, providing utmost flexibility to users.”
Source: Eyenuk, Inc.